Carregant...
Targeting RNA helicase DHX33 blocks Ras‐driven lung tumorigenesis in vivo
Ras has been found to be mutated in 30% of non‐small cell lung cancers, and its mutation has been regarded as a causal factor underlying tumorigenesis. However, no successful medicine has been developed so far to inhibit Ras for lung cancer treatment. We have previously identified DHX33 as a Ras dow...
Guardat en:
| Publicat a: | Cancer Sci |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540983/ https://ncbi.nlm.nih.gov/pubmed/32767810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14601 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|